Gladstone scientists show how a type of neuron improves procedural learning
Study may lead to new treatments for diseases like multiple sclerosis
Scientists develop a cheaper, quicker, and more reliable stem cell–based technology to facilitate drug discovery
E-Scape Bio, a Gladstone spin-off company, extends its Series A financing to generate novel therapies to treat neurodegenerative disorders
Cells associated with seizures, schizophrenia, and ADHD found in the same region of the brain.
SAN FRANCISCO, CA—Scientists from the Gladstone Institutes identified that mutations in a protein commonly linked to frontotemporal dementia (FTD) result in obsessive-like behaviors.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF), identified a common mechanism in two forms of neurodegeneration that affect young adults or the elderly.
Scientists at the Gladstone Institutes scored a rare two-for-one gain by discovering an enzyme that controls the levels of a protein implicated in both Alzheimer’s disease and frontotemporal dementia.
SAN FRANCISCO, CA—New details learned about a key cellular protein could lead to treatments for neurodegenerative diseases, such as Parkinson’s, Huntington’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS).
SAN FRANCISCO, CA—Gladstone Senior Investigator Katerina Akassoglou, PhD, was awarded a prestigious multi-year, multi-million dollar grant from the National Institute of Neurological Disorders and Stroke (NINDS).